Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2018/V15/I1/62

[1] 刘功松. 泮托拉唑治疗消化性溃疡的疗效分析[J].临床医学研究与实践,2017,2(4):33-34.
[2] 崔秀红. 泮托拉唑与奥美拉唑治疗十二指肠溃疡的疗效观察[J].中国现代药物应用,2016,10(1):189-190.
[3] 庞海霞. 泮托拉唑与奥美拉唑治疗胃溃疡的临床效果观察[J].吉林医学,2015,(12):2582-2583.
[4] 麦国. 泮托拉唑联合多潘立酮片治疗反流性食管炎的临床疗效研究[J].当代医学,2015,(12):120-120,121.
[5] 李蓓. 注射用泮托拉唑钠致双眼视力障碍2例[J].中国药物评价,2013,30(2):109-110.
[6] 赵莲英,黄阳,郭莹莹.注射用泮托拉唑钠静脉滴注致血白细胞减少1例[J].中国药业,2013,22(21):63.
[7] 王维波,王继美.注射用泮托拉唑钠致严重过敏样反应1例[J].中国药物警戒,2013,10(3):186.
[8] 李波,姜黎,蔡亚南,等.注射用泮托拉唑钠致急性喉头水肿1例[J].中国药物警戒,2016,13(1):57-57,60.
[9] 曹明雪,吴荣荣,刘峰,群,等.泮托拉唑钠致肝损害1例[J]. 医药导报,2012,31(6):822.
[10] Wedemeyer R S, Blume H.Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update[J]. Drug Saf,2014,37(4):201-211.
[11] 翟丽华,王启仪,沙卫红,等.不同剂量泮托拉唑对消化性溃疡并出血高危患者胃内 pH 的影响[J].新医学,2015,46(4):254-258.
[12] 卓越,张雪梅.不同剂量泮托拉唑对CYP2C19 PMs消化性溃疡个体药动学和药效的影响[J].黑龙江医药科学,2013,36(2):14-15.
[13] Kita T, Sakaeda T, Aoyama N, et al.Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations[J]. Biol Pharm Bull,2002,25(7): 923-927.
[14] Frye R F, Zgheib N K, Matzke G R, et al.Liver disease selectively modulates cytochrome P450-mediated metabolism[J]. Clin Pharmacol Ther,2006,80(3):235-245.
[15] 邵建国,李克庆,蒋文,等.不同细胞色素P450 2C19基因型肝病合并消化性溃疡患者泮托拉唑钠血药浓度测定[J].胃肠病学,2008,13(5):297-299.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.